Evolution of CLL treatment â€" from chemoimmunothe therapy

Nature Reviews Clinical Oncology 15, 510-527 DOI: 10.1038/s41571-018-0037-8

Citation Report

#	Article	IF	CITATIONS
1	Chimeric antigen receptor-modified T cell therapy in chronic lymphocytic leukemia. Journal of Hematology and Oncology, 2018, 11, 130.	17.0	25
2	Biclonal <i>IGHV</i> â€4â€34 hairy cell leukemia variant and CLL ―successful treatment with ibrutinib and venetoclax. American Journal of Hematology, 2018, 93, 1568-1569.	4.1	24
3	Inactivation of Prostaglandin E2 as a Mechanism for UGT2B17-Mediated Adverse Effects in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2019, 9, 606.	2.8	12
4	Chronic lymphocytic leukaemia: from genetics to treatment. Nature Reviews Clinical Oncology, 2019, 16, 684-701.	27.6	154
5	Long non-coding RNA GAS5 regulates human B lymphocytic leukaemia tumourigenesis and metastasis by sponging miR-222. Cancer Biomarkers, 2019, 26, 385-392.	1.7	20
6	Safety and Efficacy of Bendamustine Monotherapy in the First-Line Treatment of Patients with Chronic Lymphocytic Leukemia: Polish Lymphoma Research Group Real-Life Analysis. Chemotherapy, 2019, 64, 155-162.	1.6	0
7	The Mithralog EC-7072 Induces Chronic Lymphocytic Leukemia Cell Death by Targeting Tonic B-Cell Receptor Signaling. Frontiers in Immunology, 2019, 10, 2455.	4.8	4
8	Venetoclax: A Review in Relapsed/Refractory Chronic Lymphocytic Leukemia. Targeted Oncology, 2019, 14, 493-504.	3.6	6
9	Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer Journal, 2019, 9, 75.	6.2	43
10	Observational evidence from patients diagnosed with chronic lymphocytic leukaemia (CLL)Âin Finland between 2005â€2015 show improved survival over time. European Journal of Haematology, 2019, 103, 190-199.	2.2	2
11	Update on the role of venetoclax and rituximab in the treatment of relapsed or refractory CLL. Therapeutic Advances in Hematology, 2019, 10, 204062071984469.	2.5	3
12	Gain of the short arm of chromosome 2 (2p gain) has a significant role in drugâ€resistant chronic lymphocytic leukemia. Cancer Medicine, 2019, 8, 3131-3141.	2.8	10
13	Catalytic asymmetric acetalization of carboxylic acids for access to chiral phthalidyl ester prodrugs. Nature Communications, 2019, 10, 1675.	12.8	37
14	Molecular Players in Hematologic Tumor Cell Trafficking. Frontiers in Immunology, 2019, 10, 156.	4.8	40
15	Going through Changes: Surface IgM Levels during CLL Therapy with Ibrutinib. Clinical Cancer Research, 2019, 25, 2372-2374.	7.0	0
16	Impact of Donor Type and Melphalan Dose on Allogeneic Transplantation Outcomes for Patients with Lymphoma. Biology of Blood and Marrow Transplantation, 2019, 25, 1340-1346.	2.0	7
17	Ibrutinib therapy downregulates AID enzyme and proliferative fractions in chronic lymphocytic leukemia. Blood, 2019, 133, 2056-2068.	1.4	14
18	Cost-effectiveness of New Targeted Agents in the Treatment of Chronic Lymphocytic Leukemia. Cancer Journal (Sudbury, Mass), 2019, 25, 418-427.	2.0	8

#	Article	IF	CITATIONS
19	The importance of B cell receptor isotypes and stereotypes in chronic lymphocytic leukemia. Leukemia, 2019, 33, 287-298.	7.2	39
20	Acalabrutinib and its use in treatment of chronic lymphocytic leukemia. Future Oncology, 2019, 15, 579-589.	2.4	23
21	Hepatocyte Growth Factor: A Microenvironmental Resource for Leukemic Cell Growth. International Journal of Molecular Sciences, 2019, 20, 292.	4.1	10
22	Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lymphocytic leukemia. Blood, 2019, 133, 1011-1019.	1.4	168
23	Blood and Guts: Diarrhea from Colonic Involvement in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. Digestive Diseases and Sciences, 2019, 64, 345-348.	2.3	1
24	Long-term efficacy and safety of first-line ibrutinib treatment for patients with CLL/SLL: 5 years of follow-up from the phase 3 RESONATE-2 study. Leukemia, 2020, 34, 787-798.	7.2	321
25	Percutaneous coronary intervention and inâ€hospital outcomes in patients with leukemia: a nationwide analysis. Catheterization and Cardiovascular Interventions, 2020, 96, 53-63.	1.7	20
26	PI3K-p110δ contributes to antibody responses by macrophages in chronic lymphocytic leukemia. Leukemia, 2020, 34, 451-461.	7.2	8
27	Selective inhibition of PI3Kγ affects survival and proliferation of chronic lymphocytic leukemia B cells. Leukemia and Lymphoma, 2020, 61, 455-459.	1.3	1
28	The BET inhibitor GS-5829 targets chronic lymphocytic leukemia cells and their supportive microenvironment. Leukemia, 2020, 34, 1588-1598.	7.2	18
29	Reassessing the role of chemoimmunotherapy in chronic lymphocytic leukemia. Expert Review of Hematology, 2020, 13, 31-38.	2.2	5
30	Antihistamines are synergistic with Bruton's tyrosine kinase inhibiter ibrutinib mediated by lysosome disruption in chronic lymphocytic leukemia (CLL) cells. Leukemia Research, 2020, 96, 106423.	0.8	5
31	The combination of venetoclax and rituximab for the treatment of patients with recurrent chronic lymphocytic leukemia. Expert Review of Hematology, 2020, 13, 885-894.	2.2	2
32	Realâ€world outcomes for 205 patients with chronic lymphocytic leukemia treated with ibrutinib. European Journal of Haematology, 2020, 105, 646-654.	2.2	34
33	Longitudinal CITE-Seq profiling of chronic lymphocytic leukemia during ibrutinib treatment: evolution of leukemic and immune cells at relapse. Biomarker Research, 2020, 8, 72.	6.8	19
34	Treatment algorithm for Japanese patients with chronic lymphocytic leukemia in the era of novel targeted therapies. Journal of Clinical and Experimental Hematopathology: JCEH, 2020, 60, 130-137.	0.8	3
35	<p>lbrutinib in Chronic Lymphocytic Leukemia: Clinical Applications, Drug Resistance, and Prospects</p> . OncoTargets and Therapy, 2020, Volume 13, 4877-4892.	2.0	19
36	Resveratrol Enhances mRNA and siRNA Lipid Nanoparticles Primary CLL Cell Transfection. Pharmaceutics, 2020, 12, 520.	4.5	16

#	Article	IF	CITATIONS
37	Autoimmune Complications in Chronic Lymphocytic Leukemia in the Era of Targeted Drugs. Cancers, 2020, 12, 282.	3.7	22
38	Management strategies and clinical outcomes of acute myocardial infarction in leukaemia patients: Nationwide insights from United StatesÂhospitalisations. International Journal of Clinical Practice, 2020, 74, e13476.	1.7	9
39	Oxidation Impacts the Intracellular Signaling Machinery in Hematological Disorders. Antioxidants, 2020, 9, 353.	5.1	6
40	An Updated Perspective on Current Prognostic and Predictive Biomarkers in Chronic Lymphocytic Leukemia in the Context of Chemoimmunotherapy and Novel Targeted Therapy. Cancers, 2020, 12, 894.	3.7	22
41	Significance of Selective Protein Degradation in the Development of Novel Targeted Drugs and Its Implications in Cancer Therapy. Advanced Therapeutics, 2020, 3, 1900210.	3.2	2
42	Evolution in the management of chronic lymphocytic leukemia in Japan: should MRD negativity be the goal?. International Journal of Hematology, 2020, 111, 642-656.	1.6	1
43	mTOR inhibitor use in head and neck squamous cell carcinoma: A metaâ€analysis on survival, tumor response, and toxicity. Laryngoscope Investigative Otolaryngology, 2020, 5, 243-255.	1.5	14
44	Combining ibrutinib and checkpoint blockade improves CD8+ T-cell function and control of chronic lymphocytic leukemia in Em-TCL1 mice. Haematologica, 2021, 106, 968-977.	3.5	26
45	Apoptotic effect of berberine via Bclâ€2, <scp>ROR1,</scp> and mirâ€21 in patients with <scp>B hronic</scp> lymphocytic leukemia. Phytotherapy Research, 2021, 35, 2025-2033.	5.8	12
46	Ibrutinib for improved chimeric antigen receptor Tâ€cell production for chronic lymphocytic leukemia patients. International Journal of Cancer, 2021, 148, 419-428.	5.1	42
47	Effects of CD20 antibodies and kinase inhibitors on B ell receptor signalling and survival of chronic lymphocytic leukaemia cells. British Journal of Haematology, 2021, 192, 333-342.	2.5	5
48	In vivo, ex vivo and in vitro dasatinib activity in chronic lymphocytic leukemia. Oncology Letters, 2021, 21, 285.	1.8	4
49	Endogenous Stimuliâ€Activatable Nanomedicine for Immune Theranostics for Cancer. Advanced Functional Materials, 2021, 31, 2100386.	14.9	36
50	TH2/TH1 Shift Under Ibrutinib Treatment in Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2021, 11, 637186.	2.8	17
51	The Evolving Landscape of Chronic Lymphocytic Leukemia on Diagnosis, Prognosis and Treatment. Diagnostics, 2021, 11, 853.	2.6	15
52	Eradicating Minimal Residual Disease in Chronic Lymphocytic Leukemia. Advances in Oncology, 2021, 1, 249-262.	0.2	1
53	Chronic lymphocytic leukemia and the skin: implications for the dermatologist. International Journal of Dermatology, 2022, 61, 519-531.	1.0	9
54	Preexisting and treatment-emergent autoimmune cytopenias in patients with CLL treated with targeted drugs. Blood, 2021, 137, 3507-3517.	1.4	30

#	Article	IF	CITATIONS
55	NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications. International Journal of Molecular Sciences, 2021, 22, 6665.	4.1	11
56	Impact of Immune Parameters and Immune Dysfunctions on the Prognosis of Patients with Chronic Lymphocytic Leukemia. Cancers, 2021, 13, 3856.	3.7	12
57	TAp63 and BCL2 expression are co-affected by cell-extrinsic signals in chronic lymphocytic leukemia. Leukemia and Lymphoma, 2021, 62, 1-4.	1.3	1
58	MYC: a multipurpose oncogene with prognostic and therapeutic implications in blood malignancies. Journal of Hematology and Oncology, 2021, 14, 121.	17.0	72
59	LYmphoid NeXt-Generation Sequencing (LYNX) Panel. Journal of Molecular Diagnostics, 2021, 23, 959-974.	2.8	11
60	Acalabrutinib in the treatment of chronic lymphocytic leukemia: a review of recent evidence. Journal of Modern Oncology, 2021, 23, 332-338.	0.3	0
61	The road to chemotherapy-free treatment in chronic lymphocytic leukaemia. Current Opinion in Oncology, 2021, 33, 670-680.	2.4	6
62	Targeting Autophagy Triggers Apoptosis and Complements the Action of Venetoclax in Chronic Lymphocytic Leukemia Cells. Cancers, 2021, 13, 4557.	3.7	12
63	Combined ibrutinib and venetoclax treatment vs single agents in the <i>TCL1</i> mouse model of chronic lymphocytic leukemia. Blood Advances, 2021, 5, 5410-5414.	5.2	20
64	Anti-Tumour Activity of Glycodendrimer Nanoparticles in a Subcutaneous MEC-1 Xenograft Model of Human Chronic Lymphocytic Leukemia. Anti-Cancer Agents in Medicinal Chemistry, 2020, 20, 325-334.	1.7	6
65	Rare B-Cell Non-Hodgkin's Lymphomas in Childhood and Adolescence. , 2019, , 239-247.		0
66	Treatment strategies for a rapidly evolving landscape in chronic lymphocytic leukemia management. Hematological Oncology, 2022, 40, 129-159.	1.7	4
67	Gene Expression Profiling Predicts Sensitivity of Chronic Lymphocytic Leukemia Cells to Dasatinib. HemaSphere, 2021, 5, e514.	2.7	0
68	Immunoprofiling of 4-1BB Expression Predicts Outcome in Chronic Lymphocytic Leukemia (CLL). Diagnostics, 2021, 11, 2041.	2.6	2
69	Clinical Perspectives for Leukemia Treatment During Pregnancy. , 2021, , 23-48.		0
70	Bendamustine versus chlorambucil in treatment of chronic lymphocytic leukaemia in China: a randomized, open-label, parallel-controlled, phase III clinical trial. Investigational New Drugs, 2022, 40, 349.	2.6	2
71	First-line treatment of chronic lymphocytic leukemia with ibrutinib plus obinutuzumab <i>versus</i> chlorambucil plus obinutuzumab: final analysis of the randomized, phase III iLLUMINATE trial. Haematologica, 2022, 107, 2108-2120.	3.5	53
72	Delivery strategies in treatments of leukemia. Chemical Society Reviews, 2022, 51, 2121-2144.	38.1	17

#	Article	IF	CITATIONS
74	Secondary primary malignancies after treatment with chemo-immunotherapy in treatment-naÃ ⁻ ve patients with CLL: a systematic literature review. Expert Review of Hematology, 2022, 15, 273-284.	2.2	2
75	Targeted Drug Delivery for Chronic Lymphocytic Leukemia. Pharmaceutical Research, 2022, 39, 441-461.	3.5	8
76	CD34+ cell of origin for immunoglobulin heavy chain variable region unmutated, but not mutated, chronic lymphocytic leukemia. Leukemia and Lymphoma, 2022, 63, 1617-1623.	1.3	3
77	Venetoclax consolidation after fixed-duration venetoclax plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (HOVON 139/GiVe): primary endpoint analysis of a multicentre, open-label, randomised, parallel-group, phase 2 trial. Lancet Haematology,the, 2022, 9, e190-e199	4.6	18
78	Kronik lenfositik lösemide tedavi yaklaşımları: Gerçek yaşam verisi. Mersin Üniversitesi Sağlık Bilim Dergisi, 0, , 50-55.	ıleri 0.4	0
85	Distinct Age-Related Clinical Features and Risk Assessment in Chinese With Chronic Lymphocytic Leukemia. Frontiers in Oncology, 2022, 12, .	2.8	6
86	Minimal residual disease-guided stop and start of venetoclax plus ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia (HOVON141/VISION): primary analysis of an open-label, randomised, phase 2 trial. Lancet Oncology, The, 2022, 23, 818-828.	10.7	21
87	Utility of measurable residual disease for predicting treatment outcomes with BCR- and BCL2-Targeted therapies in patients with CLL. Leukemia and Lymphoma, 2022, 63, 2765-2784.	1.3	1
88	The spectrum of subclonal <i>TP53</i> mutations in chronic lymphocytic leukemia: A next generation sequencing retrospective study. Hematological Oncology, 2022, 40, 962-975.	1.7	2
89	Anti-tumor effect of berberine on chronic lymphocytic leukemia cells. , 2022, 39, .		1
90	Ibrutinib-Associated Cardiotoxicity: From the Pharmaceutical to the Clinical. Drug Design, Development and Therapy, 0, Volume 16, 3225-3239.	4.3	6
91	Targeted therapies in CLL/SLL and the cumulative incidence of infection: A systematic review and meta-analysis. Frontiers in Pharmacology, 0, 13, .	3.5	2
92	CD160 receptor in CLL: Current state and future avenues. Frontiers in Immunology, 0, 13, .	4.8	4
93	Kinase inhibitor therapies for Chronic lymphocytic leukaemia (CLL): SYK, BTK and PI3K inhibitors. , 0, 19, 30-35.		0
94	Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia. Frontiers in Oncology, 0, 12, .	2.8	1
95	Expert consensus on the management of chronic lymphocytic leukaemia in Asia. Clinical and Experimental Medicine, 2023, 23, 2895-2907.	3.6	1
96	Automated quantification of measurable residual disease in chronic lymphocytic leukemia using an artificial <scp>intelligenceâ€assisted</scp> workflow. Cytometry Part B - Clinical Cytometry, 0, , .	1.5	1
97	Effectiveness of pegfilgrastim prophylaxis in preventing febrile neutropenia during R-FC chemoimmunotherapy for chronic lymphocytic leukemia: A multicenter prospective phase II study. Frontiers in Oncology, 0, 13, .	2.8	1

#	Article	IF	CITATIONS
98	Health disparity in use of novel agents for first-line therapy in Black and White patients with chronic lymphocytic leukemia in the Department of Veterans Affairs. Journal of Managed Care & Specialty Pharmacy, 2023, 29, 420-430.	0.9	1
99	BTLA dysregulation correlates with poor outcome and diminished T cell-mediated antitumor responses in chronic lymphocytic leukemia. Cancer Immunology, Immunotherapy, 2023, 72, 2529-2539.	4.2	3
100	Case Report: Rapid renal response to venetoclax monotherapy in a CLL patient with secondary membranous glomerulonephritis. Frontiers in Oncology, 0, 13, .	2.8	2
101	Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation. Leukemia, 2023, 37, 1268-1276.	7.2	4
102	Cancers hématologiques. , 2023, , 221-228.		0
103	A population level analysis of second hematological malignancies in chronic lymphocytic leukemia/small lymphocytic lymphoma survivors in the era of targeted therapies. Hematological Oncology, 2023, 41, 884-893.	1.7	0
104	Comparing the value of mono- versus coculture for high-throughput compound screening in hematological malignancies. Blood Advances, 0, , .	5.2	0
105	Lymphocyte migration and retention properties affected by ibrutinib in chronic lymphocytic leukemia. Haematologica, 2024, 109, 809-823.	3.5	2
106	Infections in patients with chronic lymphocytic leukemia. Hematology, Transfusion and Cell Therapy, 2023, 45, 387-393.	0.2	1
107	Evolution in the frontline treatment of patients with chronic lymphocytic leukemia: experience from one European center. Leukemia and Lymphoma, 2023, 64, 1655-1661.	1.3	0
108	Clinical Research in Chronic Lymphocytic Leukemia in Pakistan; A Systematic Review. Medicina (Lithuania), 2023, 59, 1483.	2.0	0
109	Zanubrutinib: past, present, and future. Blood Cancer Journal, 2023, 13, .	6.2	2
110	Cost-Effectiveness of Ibrutinib as First-line Treatment for Older Patients With Chronic Lymphocytic Leukemia in Iran. Value in Health Regional Issues, 2023, 38, 93-100.	1.2	1
111	Chronic Lymphocytic Leukemia: Novel Perspectives – How to Teach an Old Dog New Tricks. Acta Haematologica, 0, , 1-3.	1.4	0
112	Mechanisms of ferroptosis and targeted therapeutic approaches in lymphoma. Cell Death and Disease, 2023, 14, .	6.3	0
113	Treatment of Chronic Lymphocytic Leukemia in the Personalized Medicine Era. Pharmaceutics, 2024, 16, 55.	4.5	0
114	Study of the intestinal microbiota composition and the effect of treatment with intensive chemotherapy in patients recovered from acute leukemia. Scientific Reports, 2024, 14, .	3.3	0